NCT06438783

TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

A Multicenter, Open-label, Multi-cohort Phase Ib Trial Evaluating the Efficacy and Safety of TQB2928 Injection Combined With Anlotinib Hydrochloride Capsule in Relapsed/Metastatic Osteosarcoma and Other Relapsed/Metastatic Solid Tumors

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open-label, multi-cohort Phase Ib trial to evaluate the efficacy and safety of TQB2928 injection combined with anlotinib hydrochloride capsule in patients with relapsed/metastatic osteosarcoma and other relapsed/metastatic solid tumors.

Conditions

• Osteosarcoma
• Other Solid Tumors

Interventions

Type	Name	Description
DRUG	1200mg of TQB2928 injection+Anlotinib	TQB2928 is a novel humanized immunoglobulin G4 (IgG4) subtype monoclonal antibody targeting Cluster of Differentiation 47 (CD47).
DRUG	1800mg of TQB2928 injection+Anlotinib	TQB2928 is a novel humanized igG4 subtype monoclonal antibody targeting CD47.

Timeline

• Start date: 2024-02-15
• Primary completion: 2025-06-18
• Completion: 2025-06-18
• First posted: 2024-06-03
• Last updated: 2025-12-12

Locations

5 sites across 1 country: China